pheNIX trial

March 18, 2020March 18, 2020

Efficacy of Gene Therapy for PKU, HMI-102, Supported by Work in Mice

News

A single dose of HMI-102 — a candidate gene therapy for phenylketonuria (PKU) by Homology Medicines — lowered blood levels of phenylalanine and kept this amino acid‘s levels within a normal range over 48 weeks ... Read more

December 19, 2019December 19, 2019

Promising Early Data Supports Continuation of First Gene Therapy Trial for PKU, Homology Announces

News

Homology Medicines announced promising preliminary data from its trial testing the safety and efficacy of HMI-102, a candidate gene therapy for treating adults with phenylketonuria (PKU). The phase 1/2 trial, ... Read more